Compare MNSB & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNSB | NKTX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | 204 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.4M | 154.8M |
| IPO Year | N/A | 2020 |
| Metric | MNSB | NKTX |
|---|---|---|
| Price | $22.04 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 47.0K | ★ 604.5K |
| Earning Date | 04-20-2026 | 03-25-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.00 | $1.42 |
| 52 Week High | $23.44 | $2.81 |
| Indicator | MNSB | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 37.26 |
| Support Level | $21.76 | $1.95 |
| Resistance Level | $22.13 | $2.16 |
| Average True Range (ATR) | 0.56 | 0.12 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 73.65 | 9.18 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.